Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,121,291

« Back to Dashboard
Patent 6,121,291 protects PAXIL and PAXIL CR and is included in four NDAs. There have been zero Paragraph IV challenges on Paxil CR and

Protection for PAXIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in seven countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,121,291

Title: Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
Abstract:This invention relates to the use of paroxetine or a pharmaceutically acceptable salt thereof for the treatment of post-traumatic stress disorder and depression associated with withdrawal from heroin abuse.
Inventor(s): Gleason; Maurice (Newbury, GB)
Assignee: SmithKline Beecham plc (Brentford, GB)
Application Number:09/142,990
Patent Claim Types:
see list of patent claims
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 4th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Apotex Technologies
paroxetine hydrochloride
SUSPENSION;ORAL020710-001Jun 25, 1997RXYesYes6,121,291*PED► subscribeY
Apotex Technologies
paroxetine hydrochloride
TABLET;ORAL020031-001Dec 29, 1992RXYesNo6,121,291*PED► subscribeY
Apotex Technologies
paroxetine hydrochloride
TABLET;ORAL020031-002Dec 29, 1992RXYesNo6,121,291*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: 6,121,291

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
6,121,291 September 19, 2012

Foreign Priority and PCT Information for Patent: 6,121,291

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9605828Mar 20, 1996
PCT Information
PCT FiledMarch 17, 1997PCT Application Number:PCT/EP97/01353
PCT Publication Date:September 25, 1997PCT Publication Number: WO97/34602

International Patent Family for Patent: 6,121,291

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus2482► subscribe
Germany69721756► subscribe
European Patent Office0893997► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.